Study of GV20-0251 in Participants With Solid Tumor Malignancies
This is a Phase 1 and Phase 2 study of GV20-0251 being developed for the treatment of participants with advanced solid tumors, who are refractory to approved therapies or other standard of care.
Before conducting any study-specific procedures, voluntarily sign an informed co... [+9]
Participants with acute leukemia or CLL [+15]